Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
AstraZeneca
Johnson and Johnson
McKinsey
Dow

Last Updated: August 19, 2022

Investigational Drug Information for BGJ398


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug BGJ398?

BGJ398 is an investigational drug.

There have been 22 clinical trials for BGJ398. The most recent clinical trial was a Phase 2 trial, which was initiated on December 27th 2019.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Cholangiocarcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and Helsinn Healthcare SA.

There are one hundred and forty-six US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for BGJ398
TitleSponsorPhase
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 AlterationsLabcorp Drug Development, Inc.Phase 1/Phase 2
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 AlterationsHelsinn Healthcare SAPhase 1/Phase 2
Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast CancerBreast Cancer Research FoundationPhase 1

See all BGJ398 clinical trials

Clinical Trial Summary for BGJ398

Top disease conditions for BGJ398
Top clinical trial sponsors for BGJ398

See all BGJ398 clinical trials

US Patents for BGJ398

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGJ398 See Plans and Pricing Methods for treating cancer by inhibiting FGFR3/TACC3 fusion protein Astellas Pharma Inc. (Tokyo, JP) See Plans and Pricing
BGJ398 See Plans and Pricing Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) See Plans and Pricing
BGJ398 See Plans and Pricing Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) See Plans and Pricing
BGJ398 See Plans and Pricing Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) See Plans and Pricing
BGJ398 See Plans and Pricing Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) See Plans and Pricing
BGJ398 See Plans and Pricing Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Pharmacyclics LLC (Sunnyvale, CA) See Plans and Pricing
BGJ398 See Plans and Pricing Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BGJ398

Drugname Country Document Number Estimated Expiration Related US Patent
BGJ398 Australia AU2013228389 2032-03-08 See Plans and Pricing
BGJ398 Brazil BR112014021897 2032-03-08 See Plans and Pricing
BGJ398 Canada CA2865388 2032-03-08 See Plans and Pricing
BGJ398 China CN104379740 2032-03-08 See Plans and Pricing
BGJ398 Eurasian Patent Organization EA029140 2032-03-08 See Plans and Pricing
BGJ398 Eurasian Patent Organization EA201491655 2032-03-08 See Plans and Pricing
BGJ398 European Patent Office EP2824181 2032-03-08 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
AstraZeneca
Johnson and Johnson
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.